StockData
Insight Molecular Diagnostics Inc. logo

Insight Molecular Diagnostics Inc. (IMDX) stock

IMDXNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 7/30
$1.78−0.08 (-4.30%)

Close on Nov 17, 2026Market cap $58.25MP/E –Yield –

Insight Molecular Diagnostics gross margin

Gross margin is gross profit as a percentage of revenue.

Insight Molecular Diagnostics's gross margin for the twelve months ending Jun 30, 2026 was 48.3%. For fiscal 2025 it was 56.7%, against 39.3% the year before. The highest annual figure on record is 64.6% in fiscal 2021.

Annual gross margin

PeriodPeriod endValueChange (pts)
FY2025Dec 31, 202556.7%+17.3
FY2024Dec 31, 202439.3%+11.9
FY2023Dec 31, 202327.5%+29.4
FY2022Dec 31, 2022-1.9%−66.5
FY2021Dec 31, 202164.6%+117.2
FY2020Dec 31, 2020-52.5%–

Quarterly gross margin

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange (pts)
Q2 FY2026Jun 30, 202665.7%+0.4
Q1 FY2026Mar 31, 202646.9%−15.1
Q4 FY2025Dec 31, 202543.5%+3.5
Q3 FY2025Sep 30, 202553.5%+10.0
Q2 FY2025Jun 30, 202565.3%+17.2
Q1 FY2025Mar 31, 202562.0%+36.4
Q4 FY2024Dec 31, 202440.0%+77.3
Q3 FY2024Sep 30, 202443.5%−14.3
Q2 FY2024Jun 30, 202448.1%−10.7
Q1 FY2024Mar 31, 202425.6%+22.2
Q4 FY2023Dec 31, 2023-37.3%−27.4
Q3 FY2023Sep 30, 202357.8%+459.3
Q2 FY2023Jun 30, 202358.7%+45.7
Q1 FY2023Mar 31, 20233.4%−61.6
Q4 FY2022Dec 31, 2022-9.9%−82.3
Q3 FY2022Sep 30, 2022-401.5%−313.5
Q2 FY2022Jun 30, 202213.1%+32.5
Q1 FY2022Mar 31, 202265.0%+58.0
Q4 FY2021Dec 31, 202172.5%+114.8
Q3 FY2021Sep 30, 2021-88.0%−79.7
Q2 FY2021Jun 30, 2021-19.4%+135.8
Q1 FY2021Mar 31, 20217.0%+988.3
Q4 FY2020Dec 31, 2020-42.3%–
Q3 FY2020Sep 30, 2020-8.3%–
Q2 FY2020Jun 30, 2020-155.2%–
Q1 FY2020Mar 31, 2020-981.3%–

More Insight Molecular Diagnostics figures

See a number that looks wrong?